• Wondering if Edwards Lifesciences at around US$84 a share still offers value, or if the best of the opportunity is already priced in? This article walks through the numbers so you can judge how the market is treating the stock today.
• Over the past week the share price has moved 3.9%, with a 6.1% return over the last 30 days, a 10.7% return over the past year and a year to date return of 1.4% decline. The 3 year and 5 year returns stand at 4.4% decline and 11.9% decline respectively.
• Recent coverage around Edwards Lifesciences has focused on the broader medical equipment space and how investor expectations are shifting between growth names and established players. This backdrop helps explain why price moves over recent months may reflect changing views on risk rather than just company specific developments.
• Despite this, Edwards Lifesciences currently records a valuation score of 0 out of 6. The next sections will walk through common valuation methods and how they apply here, before finishing with a different way of thinking about value that can add extra context to the raw numbers.

Edwards Lifesciences scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and discounting them back to today’s value. It is essentially asking what all those future cash flows are worth in today’s dollars.

For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $1.30b. Analysts provide explicit free cash flow estimates out to 2028, with Simply Wall St extrapolating further projections through to 2035. For example, projected free cash flow for 2028 is $1.93b, with discounted values provided for each year in the 10 year projection window.

Aggregating these discounted cash flows results in an estimated intrinsic value of about $81.15 per share. At a current share price of around $84, the DCF output suggests the stock is roughly 3.7% above this estimate, which sits within a fairly tight band.

Result: ABOUT RIGHT

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Edwards Lifesciences Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it links what you pay for each share to the earnings that company is currently generating. Higher growth expectations and lower perceived risk typically justify a higher P/E, while slower expected growth or higher risk tend to point to a lower, more conservative P/E being seen as normal.

Edwards Lifesciences currently trades on a P/E of 45.1x. This sits above both the Medical Equipment industry average P/E of 25.1x and the broader peer group average of 25.9x. To add more context, Simply Wall St calculates a proprietary “Fair Ratio” for Edwards Lifesciences of 33.5x. This Fair Ratio reflects factors such as the company’s earnings growth profile, its industry, profit margins, market capitalization and risk characteristics.

Because the Fair Ratio folds in these elements, it can be more informative than a simple comparison against peers or the industry average alone. Setting the actual P/E of 45.1x against the Fair Ratio of 33.5x suggests the shares trade at a premium to what this framework would imply.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Consider Narratives as your way of attaching a clear story to the numbers by setting your own view on Edwards Lifesciences' future revenue, earnings and margins, linking that story to a forecast and then to a fair value that you can compare with the current price to help inform your decision. All of this is available within an easy tool on Simply Wall St's Community page that updates automatically when new information like news or earnings arrives. One investor who agrees with the higher analyst target of US$110 might build a Narrative that assumes the LAA closure expansion and products like EVOQUE and Sapien M3 support stronger growth and higher margins. Another investor who aligns more with the US$84 low target might create a more cautious Narrative that leans on tariff, competition and investment risks. This gives you two clear, quantified stories around the same stock.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.